Skip to content
You can now search across every topic, entity and event.What's new
Sound Bioventures
OrganisationGB

Sound Bioventures

Early-stage biotech VC; participated in Cytospire's £61m Series A.

Last refreshed: 13 May 2026 · Appears in 1 active topic

Timeline for Sound Bioventures

#4 5 May

Cytospire's £61m oncology Series A oversubscribed

UK Startups and Innovation
View full timeline →
Follow UK Startups and Innovation →

Background

Sound Bioventures participated in Cytospire's £61m Series A in May 2026 alongside Abingworth, Servier Ventures, LifeArc Ventures, and Medical Incubator Japan. Cytospire is developing CYT X300, a pan-gamma delta T cell engager for solid tumours.

Sound Bioventures is a biotech venture firm focused on early-stage therapeutic discovery and development. It has a limited public disclosure profile; deal participation in the Cytospire round alongside established European and Japanese biotech investors suggests an institutional vehicle with biotech sector expertise. The firm's co-investment with LifeArc Ventures and Abingworth signals a broadly UK and European-oriented mandate for this deal.

Common Questions
What is Sound Bioventures?
Sound Bioventures is an early-stage biotech venture firm with a limited public profile. It participated in Cytospire's £61m Series A oncology round in May 2026.Source: Lowdown uk-startups-and-innovation U#4
Who are the investors in Cytospire's oncology round?
Cytospire's £61m Series A was backed by Abingworth, Servier Ventures, Sound Bioventures, LifeArc Ventures, and Medical Incubator Japan.Source: Lowdown uk-startups-and-innovation U#4
What is Cytospire developing?
Cytospire is developing CYT X300, a first-in-class pan-gamma delta T cell engager targeting solid tumours, funded through a £61m Series A in May 2026.Source: Lowdown uk-startups-and-innovation U#4